Why Teva's Stock Could Crash Another 50% Post author:Sam Post published:November 7, 2017 Post category:BioPharma Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace You Might Also Like 3 Biotechs Facing Big FDA Decisions in October September 26, 2017 Astellas Takes a $387 Million+ Loss as It Shuts Down SoCal's Agensys, Inc. July 26, 2017 iCAD Wins FDA Approval for PowerLook Tomo Detection March 26, 2017
